• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

女性对多基因乳腺癌风险信息的反应和理解。

Women's responses and understanding of polygenic breast cancer risk information.

机构信息

Prince of Wales Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW, 2052, Australia.

The University of Queensland Diamantina Institute, Dermatology Research Centre, The University of Queensland, Brisbane, QLD, 4102, Australia.

出版信息

Fam Cancer. 2020 Oct;19(4):297-306. doi: 10.1007/s10689-020-00185-2.

DOI:10.1007/s10689-020-00185-2
PMID:32430685
Abstract

It is estimated that polygenic factors can explain up to 18% of familial breast cancer. Clinical implementation of polygenic testing has begun, with several commercial laboratories now testing. Despite commercial implementation, there is little research investigating how women respond and understand polygenic risk information. This study aimed to explore women's experience receiving their personalised polygenic risk score (PRS) and compare responses of women at different levels of polygenic risk. Eligible participants were affected and unaffected women from families clinically assessed to be at high risk for breast cancer who had received their personalised PRS as part of the Variants in Practice Psychosocial Study (ViPPs). In-depth semi-structured interviews were conducted with 21 women (mean age 53.4 years) up to four weeks after receiving their PRS. Interviews were transcribed verbatim and analysed using thematic analysis. Eleven women received a PRS that was in the top quartile of PRS distribution and 10 in the lowest quartile. Women's lived experience with breast cancer informed how they responded to their PRS, constructed and made sense of breast cancer risk following receipt of their PRS, and integrated this new information into their breast cancer risk management. Regardless of polygenic risk level, all participants demonstrated broad knowledge of concepts related to polygenic information and were able to accurately describe the implications of their PRS. Receiving PRS did not appear to negatively impact women's reported distress levels. Our findings suggest polygenic breast cancer information is well received and understood by women at high-risk for breast cancer.

摘要

据估计,多基因因素可以解释高达 18%的家族性乳腺癌。多基因检测已开始临床实施,目前已有几家商业实验室进行检测。尽管已经商业化,但很少有研究调查女性如何对多基因风险信息做出反应和理解。本研究旨在探讨女性接受个性化多基因风险评分(PRS)的体验,并比较不同多基因风险水平女性的反应。合格的参与者是来自临床评估为乳腺癌高危家族的受影响和未受影响的女性,她们已经收到了个性化的 PRS,作为 Variants in Practice Psychosocial Study (ViPPs) 的一部分。在收到 PRS 后的四周内,对 21 名女性(平均年龄 53.4 岁)进行了深入的半结构化访谈。访谈逐字记录,并使用主题分析进行分析。11 名女性收到的 PRS 处于 PRS 分布的前四分之一,10 名女性收到的 PRS 处于最低四分之一。女性的乳腺癌生活经历影响了她们对 PRS 的反应,构建和理解了收到 PRS 后的乳腺癌风险,并将这一新信息纳入了她们的乳腺癌风险管理中。无论多基因风险水平如何,所有参与者都表现出对与多基因信息相关的概念的广泛了解,并且能够准确描述他们的 PRS 的含义。接受 PRS 似乎并没有对女性报告的焦虑水平产生负面影响。我们的研究结果表明,多基因乳腺癌信息受到高乳腺癌风险女性的欢迎和理解。

相似文献

1
Women's responses and understanding of polygenic breast cancer risk information.女性对多基因乳腺癌风险信息的反应和理解。
Fam Cancer. 2020 Oct;19(4):297-306. doi: 10.1007/s10689-020-00185-2.
2
Influence of lived experience on risk perception among women who received a breast cancer polygenic risk score: 'Another piece of the pie'.经历对接受乳腺癌多基因风险评分女性风险感知的影响:“另一块馅饼”。
J Genet Couns. 2021 Jun;30(3):849-860. doi: 10.1002/jgc4.1384. Epub 2021 Jan 19.
3
Development and pilot testing of a leaflet informing women with breast cancer about genomic testing for polygenic risk.制定并初步测试了一份告知乳腺癌女性有关多基因风险基因组检测的传单。
Fam Cancer. 2019 Apr;18(2):147-152. doi: 10.1007/s10689-018-0104-4.
4
Uptake of polygenic risk information among women at increased risk of breast cancer.具有乳腺癌风险升高的女性对多基因风险信息的接受情况。
Clin Genet. 2020 Mar;97(3):492-501. doi: 10.1111/cge.13687. Epub 2019 Dec 25.
5
Making Sense of SNPs: Women's Understanding and Experiences of Receiving a Personalized Profile of Their Breast Cancer Risks.理解单核苷酸多态性:女性对获取个人乳腺癌风险概况的理解与经历
J Genet Couns. 2018 Jun;27(3):702-708. doi: 10.1007/s10897-017-0162-z. Epub 2017 Nov 22.
6
Breast cancer polygenic risk scores: a 12-month prospective study of patient reported outcomes and risk management behavior.乳腺癌多基因风险评分:一项为期 12 个月的患者报告结局和风险管理行为的前瞻性研究。
Genet Med. 2021 Dec;23(12):2316-2323. doi: 10.1038/s41436-021-01288-6. Epub 2021 Aug 2.
7
Psychosocial and behavioral impact of breast cancer risk assessed by testing for common risk variants: protocol of a prospective study.通过检测常见风险变异评估乳腺癌风险的心理社会和行为影响:一项前瞻性研究方案
BMC Cancer. 2017 Jul 18;17(1):491. doi: 10.1186/s12885-017-3485-0.
8
Impact of Personalized Genetic Breast Cancer Risk Estimation With Polygenic Risk Scores on Preventive Endocrine Therapy Intention and Uptake.多基因风险评分的个性化遗传性乳腺癌风险评估对预防性内分泌治疗意愿和接受情况的影响。
Cancer Prev Res (Phila). 2021 Feb;14(2):175-184. doi: 10.1158/1940-6207.CAPR-20-0154. Epub 2020 Oct 23.
9
Breast cancer polygenic risk scores in the clinical cancer genetic counseling setting: Current practices and impact on patient management.临床癌症遗传咨询环境中的乳腺癌多基因风险评分:当前的实践和对患者管理的影响。
J Genet Couns. 2021 Apr;30(2):588-597. doi: 10.1002/jgc4.1347. Epub 2020 Oct 30.
10
A qualitative study on Singaporean women's views towards breast cancer screening and Single Nucleotide Polymorphisms (SNPs) gene testing to guide personalised screening strategies.一项关于新加坡女性对乳腺癌筛查和单核苷酸多态性(SNP)基因检测以指导个体化筛查策略的看法的定性研究。
BMC Cancer. 2017 Nov 21;17(1):776. doi: 10.1186/s12885-017-3781-8.

引用本文的文献

1
Considering Clinical Implementation of Polygenic Scores in Hereditary Cancer Risk Assessment: Recipients' Perspectives on Influencing Factors and Strategies.遗传性癌症风险评估中多基因评分的临床应用考量:接受者对影响因素及策略的看法
Patient. 2025 Jun 28. doi: 10.1007/s40271-025-00747-5.
2
Understanding Genetic Screening: Harnessing Health Information to Prevent Disease Risks.了解基因筛查:利用健康信息预防疾病风险。
Int J Med Sci. 2025 Jan 21;22(4):903-919. doi: 10.7150/ijms.101219. eCollection 2025.
3
Polygenic risk scores in the clinic: a systematic review of stakeholders' perspectives, attitudes, and experiences.
临床中的多基因风险评分:对利益相关者观点、态度和经历的系统评价
Eur J Hum Genet. 2025 Mar;33(3):266-280. doi: 10.1038/s41431-024-01747-z. Epub 2024 Nov 23.
4
Using polygenic risk modification to improve breast cancer prevention: study protocol for the PRiMo multicentre randomised controlled trial.多基因风险修饰改善乳腺癌预防:PRiMo 多中心随机对照试验研究方案。
BMJ Open. 2024 Aug 5;14(8):e087874. doi: 10.1136/bmjopen-2024-087874.
5
The role of polygenic risk scores in breast cancer risk perception and decision-making.多基因风险评分在乳腺癌风险认知和决策中的作用。
J Community Genet. 2023 Oct;14(5):489-501. doi: 10.1007/s12687-023-00655-x. Epub 2023 Jun 13.
6
Risk-Stratified Breast Cancer Screening Incorporating a Polygenic Risk Score: A Survey of UK General Practitioners' Knowledge and Attitudes.基于多基因风险评分的风险分层乳腺癌筛查:英国全科医生知识和态度的调查。
Genes (Basel). 2023 Mar 16;14(3):732. doi: 10.3390/genes14030732.
7
A qualitative study exploring the consumer experience of receiving self-initiated polygenic risk scores from a third-party website.一项探索消费者自身从第三方网站获取多基因风险评分的体验的定性研究。
Eur J Hum Genet. 2023 Apr;31(4):424-429. doi: 10.1038/s41431-022-01203-w. Epub 2022 Oct 4.
8
The current status of risk-stratified breast screening.风险分层乳腺癌筛查的现状。
Br J Cancer. 2022 Mar;126(4):533-550. doi: 10.1038/s41416-021-01550-3. Epub 2021 Oct 26.
9
Information needs on breast cancer genetic and non-genetic risk factors in relatives of women with a BRCA1/2 or PALB2 pathogenic variant.关于携带 BRCA1/2 或 PALB2 致病性变异的女性亲属的乳腺癌遗传和非遗传风险因素的信息需求。
Breast. 2021 Dec;60:38-44. doi: 10.1016/j.breast.2021.08.011. Epub 2021 Aug 23.